In a report released yesterday, Anthony Vendetti from Maxim Group reiterated a Buy rating on Sientra (SIEN – Research Report), with a price target of $5.00. The company’s shares closed last Friday at $1.19, close to its 52-week low of $1.18.
According to TipRanks.com, Vendetti is a 3-star analyst with an average return of 1.0% and a 35.0% success rate. Vendetti covers the Healthcare sector, focusing on stocks such as Guardion Health Sciences, ReShape Lifesciences, and Dermata Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Sientra with a $7.20 average price target, representing a 425.5% upside. In a report released yesterday, Canaccord Genuity also maintained a Buy rating on the stock with a $5.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Based on Sientra’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $22.65 million and GAAP net loss of $16.07 million. In comparison, last year the company earned revenue of $17.89 million and had a GAAP net loss of $21.24 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Sientra, Inc. operates as a medical aesthetics company, which engages in developing and commercializing plastic surgery implantable devices. It operates through two reportable segments: Breast Products and miraDry. The Breast Products segment focuses on sales of its breast implants, tissue expanders and scar management products under the brands Sientra, AlloX2, Dermaspan, Softspan and BIOCORNEUM. The miraDry segment focuses on sales of the miraDry System, consisting of a console and a handheld device which uses consumable single-use bioTips. The company was founded by Hani M. Zeini in August 29, 2003 and is headquartered in Santa Barbara, CA.
Read More on SIEN:
- Maxim Group Remains a Buy on Biolase (BIOL)
- Maxim Group Thinks Heritage Global’s Stock is Going to Recover
- Analysts’ Top Services Picks: Research Solutions (RSSS), Flux Power Holdings (FLUX)
- Analysts Offer Insights on Healthcare Companies: Daré Bioscience (DARE) and Guardion Health Sciences (GHSI)
- Maxim Group Thinks Usio’s Stock is Going to Recover
